155 related articles for article (PubMed ID: 24728124)
1. The novel bladder preservation therapy BOAI-CDDP-radiation (OMC-regimen): a new treatment option for invasive bladder cancer patients with lymph node metastasis.
Azuma H; Inamoto T; Takahara K; Nomi H; Hirano H; Ibuki N; Uehara H; Komura K; Minami K; Uchimoto T; Saito K; Takai T; Tanda N; Yamamoto K; Narumi Y; Kiyama S
Int J Oncol; 2014 Jun; 44(6):1895-903. PubMed ID: 24728124
[TBL] [Abstract][Full Text] [Related]
2. A great option for elderly patients with locally invasive bladder cancer, BOAI-CDDP-radiation (OMC regimen).
Azuma H; Inamoto T; Takahara K; Nomi H; Hirano H; Uehara H; Komura K; Minami K; Kouno J; Kotake Y; Abe H; Takagi S; Ibuki N; Yamamoto K; Narumi Y; Kiyama S
Int J Oncol; 2013 Oct; 43(4):1087-94. PubMed ID: 23934264
[TBL] [Abstract][Full Text] [Related]
3. Tetramodal therapy using balloon-occluded arterial infusion of anticancer agents, the Azuma regimen, for lymph node-involved bladder cancer.
Azuma H; Inamoto T; Takahara K; Ibuki N; Nomi H; Komura K; Uehara H; Minami K; Yamamoto K; Narumi Y
Int J Oncol; 2019 Jan; 54(1):167-176. PubMed ID: 30387836
[TBL] [Abstract][Full Text] [Related]
4. Effect of a novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen).
Azuma H; Inamoto T; Takahara K; Nomi H; Uehara H; Komura K; Minami K; Kouno J; Kotake Y; Abe H; Takagi S; Yamamoto K; Narumi Y; Kiyama S
Int J Oncol; 2013 Jul; 43(1):79-87. PubMed ID: 23624911
[TBL] [Abstract][Full Text] [Related]
5. Utility of the novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen), for elderly patients with invasive bladder cancer.
Azuma H; Inamoto T; Ibuki N; Ubai T; Kotake Y; Takahara K; Kiyama S; Nomi H; Uehara H; Komura K; Yamamoto K; Narumi Y; Katsuoka Y
Int J Oncol; 2011 Jan; 38(1):13-24. PubMed ID: 21109921
[TBL] [Abstract][Full Text] [Related]
6. Novel bladder preservation therapy for locally invasive bladder cancer: combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation.
Azuma H; Inamoto T; Ibuki N; Ubai T; Kotake Y; Takahara K; Kiyama S; Nomi H; Uehara H; Komura K; Yamamoto K; Narumi Y; Katsuoka Y
Int J Oncol; 2010 Oct; 37(4):773-85. PubMed ID: 20811698
[TBL] [Abstract][Full Text] [Related]
7. Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation.
Azuma H; Yamamoto K; Inamoto T; Ibuki N; Kotake Y; Sakamoto T; Kiyama S; Ubai T; Takahara K; Segawa N; Narumi Y; Katsuoka Y
Am J Clin Oncol; 2009 Dec; 32(6):592-606. PubMed ID: 19593084
[TBL] [Abstract][Full Text] [Related]
8. Novel bladder preservation therapy with Osaka Medical College regimen.
Azuma H; Inamoto T; Takahara K; Nomi H; Hirano H; Ibuki N; Uehara H; Komura K; Minami K; Uchimoto T; Saito K; Takai T; Tanda N; Yamamoto K; Narumi Y; Kiyama S
J Urol; 2015 Feb; 193(2):443-50. PubMed ID: 25167990
[TBL] [Abstract][Full Text] [Related]
9. Effect of combined therapy using balloon-occluded arterial infusion of cisplatin and hemodialysis with concurrent radiation for locally invasive bladder cancer.
Azuma H; Kotake Y; Yamamoto K; Sakamoto T; Kiyama S; Ubai T; Inamoto T; Takahara K; Matsuki M; Segawa N; Shibahara N; Katsuoka Y
Am J Clin Oncol; 2008 Feb; 31(1):11-21. PubMed ID: 18376222
[TBL] [Abstract][Full Text] [Related]
10. Optimisation of Radiation Therapy in Bladder Preservation Therapy for Patients With Clinical Stage T2N0M0 Bladder Cancer.
Nakata M; Shimbo T; Kihara A; Sato C; Hori A; Yoshioka H; Yoshida K; Nihei K
Clin Oncol (R Coll Radiol); 2022 Oct; 34(10):e430-e436. PubMed ID: 35715341
[TBL] [Abstract][Full Text] [Related]
11. Treatment Results of Radiotherapy Combined with Balloon-occluded Arterial Infusion Chemotherapy for Invasive Bladder Cancer.
Yoshioka H; Shimbo T; Yoshida K; Yoshikawa N; Uesugi Y; Yamamoto K; Azuma H; Narumi Y
Anticancer Res; 2016 Feb; 36(2):731-6. PubMed ID: 26851031
[TBL] [Abstract][Full Text] [Related]
12. Initial results of retrospective study: preoperative transurethral excision plus chemotherapy and radiation therapy and trial of bladder preservation.
Gamal El-Deen HS
J Egypt Natl Canc Inst; 2007 Jun; 19(2):133-46. PubMed ID: 19034344
[TBL] [Abstract][Full Text] [Related]
13. Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
Coen JJ; Zhang P; Saylor PJ; Lee CT; Wu CL; Parker W; Lautenschlaeger T; Zietman AL; Efstathiou JA; Jani AB; Kucuk O; Souhami L; Rodgers JP; Sandler HM; Shipley WU
J Clin Oncol; 2019 Jan; 37(1):44-51. PubMed ID: 30433852
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
[TBL] [Abstract][Full Text] [Related]
15. Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer.
Cobo M; Delgado R; Gil S; Herruzo I; Baena V; Carabante F; Moreno P; Ruiz JL; Bretón JJ; Del Rosal JM; Fuentes C; Moreno P; García E; Villar E; Contreras J; Alés I; Benavides M
Clin Transl Oncol; 2006 Dec; 8(12):903-11. PubMed ID: 17169764
[TBL] [Abstract][Full Text] [Related]
16. Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long-term results of a phase 1 trial.
Azria D; Riou O; Rebillard X; Thezenas S; Thuret R; Fenoglietto P; Pouessel D; Culine S
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):853-9. PubMed ID: 24368064
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J
Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant and adjuvant chemotherapy for locally advanced bladder carcinoma: development of novel bladder preservation approach, Osaka Medical College regimen.
Azuma H; Inamoto T; Takahara K; Ibuki N; Nomi H; Yamamoto K; Narumi Y; Ubai T
Int J Urol; 2012 Jan; 19(1):26-38. PubMed ID: 22077821
[TBL] [Abstract][Full Text] [Related]
19. Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer: experience at Sindh Institute of Urology & Transplantation (SIUT).
Tunio MA; Hashmi A; Rafi M; Qayyum A; Masood R
J Pak Med Assoc; 2011 Jan; 61(1):6-10. PubMed ID: 22368893
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.
Mitin T; George A; Zietman AL; Heney NM; Kaufman DS; Uzzo RG; Dreicer R; Wallace HJ; Souhami L; Dobelbower MC; Sandler HM; Shipley WU
Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):67-74. PubMed ID: 26700703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
